# Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With 

Source: https://onco.cc/trials/nct07227415/  
OnCo record `nct07227415` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PF-08634404, Ipilimumab, Axitinib in renal cell carcinoma, run by Pfizer, now recruiting.

## Summary

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer is a phase 1/2 interventional study registered as NCT07227415 by Pfizer, with 224 participants planned, started 2026-02-10 and due to reach its primary completion in 2027-11-02. Interventions recorded: PF-08634404, Ipilimumab, Axitinib. Conditions listed: Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07227415
- Phase: 1/2
- Setting: AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
- Sponsor: Pfizer
- Enrolled: 224

## Sources

- ClinicalTrials.gov NCT07227415: https://clinicaltrials.gov/study/NCT07227415

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Axitinib](https://onco.cc/drugs/axitinib/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [PF-08634404](https://onco.cc/drugs/pf-08634404/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct07227415.json